ERVW-1 and myasthenia gravis: Notably, AAbs targeting the epitope HERV-K-env-su(19–37) were detected in 30% of MG patients compared to 8% of HCs, as corroborated by Fisher’s exact test (p = 0.0137) (Figure 1A).